Patients & Families
Focused on Children. Driven by Impact.
Our Commitment
We are developing therapies that address the genetic causes of hearing loss, with the goal of helping children connect, communicate, and thrive.
Early intervention
Designed to support treatment in children with genetic hearing loss, when hearing is critical for speech, language, and social development.
Durable, one-time treatments
Engineered to provide sustained therapeutic benefit from a single treatment.
Restoring Human Connection
Committed to bringing new treatment options to patients and families affected by genetic hearing loss.
Clinical Trials
Advancing tomorrow’s treatments, today.
Our lead program, SKY-GJB2, is being evaluated in the SONIX Phase 1/2 clinical trial for pediatric patients with GJB2-mediated hearing loss.
We are committed to scientific rigor, patient safety, and meaningful outcomes for children and families affected by genetic hearing loss.
Expanded Access Policy
Skylark Bio focuses on conducting clinical trials to study the safety and efficacy of SKY-GJB2 in patients with GJB2-mediated hearing loss. These clinical trials are necessary for obtaining regulatory approval. We believe that participation in clinical trials is the most appropriate way for patients to access SKY-GJB2 before it is approved by a regulatory authority. We believe regulatory approval is the best way to make safe and effective medications available to patients who may benefit. Currently, we do not offer Expanded Access programs for SKY-GJB2. To learn more about our ongoing clinical trial for GJB2-mediated hearing loss, please visit our study posting on clinicaltrials.gov or sonixstudy.com.
